AUTHORS
Sergio Rodriguez-Rodriguez, MD, MSc, Eshrak Al-Shaibani, MD2, Tommy Alfaro Moya, MD3, Igor Novitzky-Basso, MD,PhD4, Ivan Pasic, BSc5, Auro Viswabandya, MBBS MD DM6, Fotios Michelis, MD, PhD7, Rajat Kumar, FRCPC8, Jonas Mattsson, MD PhD9, Dennis Dong Hwan Kim, MD/PhD10
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
ABSTRACT
Background: Chronic GvHD (cGvHD) causes immune-mediated destruction of the vascular endothelium via donor T lymphocytes. Biomarkers predicting response to ruxolitinib (RUX) therapy in patients with steroid-refractory cGvHD (SR-cGvHD) have not been well defined, with the REACH3 trial failing to identify a cytokine-based biomarker. Endothelial activation and stress index (EASIX), calculated from lactate dehydrogenase, creatinine, and platelet count, is known to be associated with treatment outcomes in acute GvHD. The present study investigated its role as a potential biomarker for long-term outcomes of RUX therapy in SR-cGvHD.
Methods: We conducted a single-center retrospective cohort study of 79 adult patients who were treated with RUX for SR-cGvHD between January 2016 and January 2025. EASIX was calculated and converted into log2-transformed scale at RUX initiation (D1), day 28, and months 2, 3, 6, and 12; log2-EASIX was analyzed as a continuous variable, with hazard ratios (HR) expressed per doubling of EASIX. Endpoints were overall survival (OS), failure-free survival (FFS), non-relapse mortality (NRM), and overall response rate (ORR; composite of complete or partial response by the NIH criteria). Univariable and multivariable Cox and logistic regression analyses were conducted to assess the association of EASIX with each endpoint.
Results: Out of 79 patients evaluated, median age was 52 years (IQR 36-64), and 42 patients (53%) were male. Donor type included matched unrelated (n=37; 47%), matched related (n=33; 42%), and haplo (n=9; 11%); 44 patients (56%) received reduced-intensity conditioning. Median time from HCT to cGvHD diagnosis was 5.7 months (IQR 4.6-8.0), with 46 patients (58%) presenting as overlap syndrome. At RUX initiation, 29 patients (37%) had severe grade cGvHD with a median of 3 organs involved (IQR 2–4). Median time interval from cGvHD diagnosis to RUX start was 10.3 months (IQR 3.9-34.3).
Median EASIX at RUX initiation was 1.32 (IQR 0.84-2.65; n=78). Each doubling of EASIX was associated with worse OS (HR 2.01, 95% CI [1.33-3.05], p<0.001) and higher NRM (HR 1.84, [1.18-2.86], p=0.007). Both persisted after adjustment for cGvHD severity and performance status (HR 2.12 for OS, [1.37-3.30], p<0.001; HR 1.93 for NRM, [1.20-3.08], p=0.006). Tertile analysis showed the same trend of worse outcomes in comparison to the lowest tertile (HR for OS, 5.38 and 8.58; HR for NRM 5.53 and 6.43 for the middle and highest tertiles). When the overall cohort was stratified according to the median EASIX value (i.e., 1.32), the 3-year OS rate was 92% vs. 72% (log-rank p=0.006), the 3-year FFS rate was 49% vs. 36% (p=0.232), and the 3-year NRM was 8% vs. 23% (p=0.028) for low vs. high EASIX.
However, Log2-EASIX was not associated with FFS (HR 1.20, [0.94-1.54], p=0.150), with ORR at day 28 (OR 0.99, [0.67-1.46], p=0.949, n=78) nor ORR at 3 months (OR 1.05, [0.69-1.60], p=0.835, n=74). Poor performance status (i.e. ECOG ≥2) was independently associated with worse OS (HR 4.92 [1.57-15.37], p=0.006) and higher NRM (cause-specific HR 7.08, [2.09-23.96], p=0.002), whereas cGvHD severity was not independently associated with any statistical endpoint.
In exploratory analysis, a higher number of organs involved at RUX initiation was inversely associated with log2-EASIX (fold-change 0.79 per organ, [0.71-0.89], p<0.001), and ECOG ≥2 was associated with higher log2-EASIX (fold-change 1.71, [1.04-2.81], p=0.039), whereas cGvHD severity, cGvHD subtype and prior acute GvHD did not show such an association. When assessing organ-specific cGvHD involvement, mouth involvement was associated with lower log2-EASIX (p=0.042), whereas gastrointestinal, musculoskeletal, ocular, liver, cutaneous, and lung involvement did not show any association. Log2-EASIX was numerically higher in patients who ever failed RUX at any time point examined, but only statistically significant at day 28 (median log2-EASIX 1.09 vs 0.35; p=0.038). Log2-EASIX did not differ by concurrent response status at any assessed timepoint (all p ≥ 0.162).
Conclusion: Higher log2-EASIX prior to RUX therapy for SR-cGvHD was independently associated with worse OS and higher NRM, whereas no association was observed with response to RUX. This suggests EASIX may identify patients at risk of death or NRM, rather than those failing to respond to RUX for SR-cGvHD treatment. Prospective, multicenter validation is required before EASIX is used for risk stratification at RUX initiation.
DISCLOSURES
Sergio Rodriguez-Rodriguez, MD, MSc: No relevant conflicts of interest to declare.